Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes.

Smushkin G, Sathananthan M, Piccinini F, Dalla Man C, Law JH, Cobelli C, Zinsmeister AR, Rizza RA, Vella A.

Diabetes. 2013 Apr;62(4):1094-101. doi: 10.2337/db12-0923. Epub 2012 Dec 18.

2.

Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.

Beysen C, Murphy EJ, Deines K, Chan M, Tsang E, Glass A, Turner SM, Protasio J, Riiff T, Hellerstein MK.

Diabetologia. 2012 Feb;55(2):432-42. doi: 10.1007/s00125-011-2382-3. Epub 2011 Dec 2.

PMID:
22134839
4.

The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study.

Schwartz SL, Lai YL, Xu J, Abby SL, Misir S, Jones MR, Nagendran S.

Metab Syndr Relat Disord. 2010 Apr;8(2):179-88. doi: 10.1089/met.2009.0049.

PMID:
20059361
5.

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.

Bays HE, Goldberg RB, Truitt KE, Jones MR.

Arch Intern Med. 2008 Oct 13;168(18):1975-83. doi: 10.1001/archinte.168.18.1975.

PMID:
18852398
6.

Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function.

Marina AL, Utzschneider KM, Wright LA, Montgomery BK, Marcovina SM, Kahn SE.

Diabetes Care. 2012 May;35(5):1119-25. doi: 10.2337/dc11-2050. Epub 2012 Mar 23.

7.

Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.

Gastaldelli A, Nauck MA, Balena R.

Metabolism. 2013 Sep;62(9):1330-9. doi: 10.1016/j.metabol.2013.05.001. Epub 2013 Jul 4.

PMID:
23831441
8.

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

Diabetes. 2002 Feb;51(2):424-9.

9.

The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.

Shang Q, Liu MK, Saumoy M, Holst JJ, Salen G, Xu G.

Am J Physiol Gastrointest Liver Physiol. 2012 Apr 15;302(8):G815-23. doi: 10.1152/ajpgi.00295.2011. Epub 2012 Jan 26.

10.

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.

Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B.

Diabetes Care. 1997 Dec;20(12):1874-9.

PMID:
9405910
11.

Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus.

Henry RR, Aroda VR, Mudaliar S, Garvey WT, Chou HS, Jones MR.

Diabetes Obes Metab. 2012 Jan;14(1):40-6. doi: 10.1111/j.1463-1326.2011.01486.x. Epub 2011 Nov 21.

12.

Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome.

Vega GL, Dunn FL, Grundy SM.

Am J Cardiol. 2011 Oct 15;108(8):1129-35. doi: 10.1016/j.amjcard.2011.06.011. Epub 2011 Aug 1.

PMID:
21813109
13.
14.

Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.

Goldberg RB, Fonseca VA, Truitt KE, Jones MR.

Arch Intern Med. 2008 Jul 28;168(14):1531-40. doi: 10.1001/archinte.168.14.1531.

PMID:
18663165
15.

Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.

Højberg PV, Vilsbøll T, Zander M, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S.

Diabet Med. 2008 Nov;25(11):1268-75. doi: 10.1111/j.1464-5491.2008.02579.x.

PMID:
19046215
16.

Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.

Jones MR, Mudaliar S, Hernandez-Triana E, Unnikrishnan AG, Lai YL, Abby SL, Misir S, Jin X, Nagendran S.

Curr Med Res Opin. 2009 Sep;25(9):2239-49. doi: 10.1185/03007990903126791.

PMID:
19622007
18.

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, Camilleri M.

Diabetes. 2007 May;56(5):1475-80. Epub 2007 Feb 15.

19.

Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.

Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA.

Exp Clin Endocrinol Diabetes. 1998;106(2):103-7.

PMID:
9628239
20.

The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.

Bock G, Dalla Man C, Micheletto F, Basu R, Giesler PD, Laugen J, Deacon CF, Holst JJ, Toffolo G, Cobelli C, Rizza RA, Vella A.

Clin Endocrinol (Oxf). 2010 Aug;73(2):189-96. doi: 10.1111/j.1365-2265.2009.03764.x. Epub 2009 Dec 18.

Items per page

Supplemental Content

Write to the Help Desk